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Aim/introduction: Circulating levels of N-terminal fragment of probrain natriuretic peptide 
(NT-proBNP) are established as a risk factor for cardiovascular disease and mortality in patients 
with diabetes, as well as in the general population. We sought to examine the possibility of NT-
proBNP as a biomarker of microvascular complications in patients with type 2 diabetes.
Materials and methods: In total, 277 outpatients with type 2 diabetes were consecutively enrolled 
as a hospital cohort. Two hundred and seventeen of these patients (132 males; mean age, 63.4 
years) were designated as cases with any of the diabetic complications (retinopathy, neuropathy, 
nephropathy, ischemic heart disease, strokes, peripheral artery disease), and 60 (42 males; mean 
age, 54.1 years) were set as controls without clinical evidence of diabetic complications. Diabetic 
complications were evaluated by medical record and routine laboratory examinations. NT-proBNP 
was measured and investigated with regard to the associations with diabetic complications.
Results: Mean NT-proBNP levels were significantly higher in patients with any of the diabetic 
complications (59 versus 33 pg/mL; P,0.0001). In logistic regression analysis, NT-proBNP 
levels .79 pg/mL, which was the highest tertile, were independently associated with a 5.04 fold 
increased risk of all complications (P,0.0051) compared to the lowest tertile (NT-proBNP levels 
,31 pg/mL). Odd ratios of cardiovascular disease and nephropathy, neuropathy, and retinopathy 
were 9.33, 6.23, 6.6 and 13.78 respectively, in patients with NT-proBNP values in the highest 
tertile (.79 pg/mL), independently of age, sex, duration of diabetes or other risk factors, such 
as body mass index or hemoglobin A1c. In addition, NT-proBNP levels were associated with 
surrogate markers of atherosclerosis, such as brachial-ankle pulse wave velocity (r=0.449, 
P,0.0001) and left ventricular hypertrophy (r=0.212, P,0.001).
Conclusion: In this hospital-based cohort of type 2 diabetes, the NT-proBNP levels were associ-
ated with systemic atherosclerosis and comorbid diabetic microvascular as well as macrovascular 
complications. It is useful to stratify high-risk diabetic patients by measuring NT-proBNP and to 
start comprehensive care for preventing the progression of diabetic complications. It is necessary 
to elucidate the underlying mechanism for the progression of diabetic complications represented 
by an elevation of NT-proBNP and to demonstrate the ability of NT-proBNP as a predictive 
global biomarker for diabetic complications in Japanese type 2 diabetic patients.
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Introduction
The N-terminal fragment of probrain natriuretic peptide (NT-proBNP) is postulated as 
a diagnostic and prognostic biomarker of heart failure and cardiovascular mortality in 
type 2 diabetes.1,2 It has been reported that patients with type 2 diabetes had increased 
levels of NT-proBNP even though they had no overt cardiovascular disease (CVD).3 The 
mechanism for the elevation of BNP was not fully elucidated. We recently reported that 
NT-proBNP could be a marker of silent myocardial ischemia in type 2 diabetes.4Vascular Health and Risk Management 2014:10 submit your manuscript | www.dovepress.com
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Diabetes mellitus retinopathy (DMR) is a common 
chronic microvascular complication. DMR has been asso-
ciated with increased all-cause and CVD mortality risk in 
both type 2 and type 1 diabetes.5 Considering these data, 
identification of DMR could possibly add to the diabetic 
patient’s CVD risk stratification.6 Also, there are several 
reports – including ours7 – that indicate the interrelation-
ships of diabetic microangiopathy with macroangiopathy.8 
Microalbuminuria reflects a generalized disturbance of 
microvascular function related to the endothelium-dependent 
mechanism. Thus, microalbuminuria is established as not 
only a marker for the risk of retinopathy, nephropathy, and 
neuropathy but also as a predictor for CVD.9 Recently, 
NT-proBNP was reported to be associated with diabetic 
complications in a large cohort of type 1 diabetes.10 It was 
proposed that NT-proBNP is a novel vascular risk factor 
reflecting systemic inflammation.
The aim of the present study was to test whether NT-
proBNP levels were associated with diabetic microvascular 
complications in Japanese type 2 diabetes.
Materials and methods
In total, 277 type 2 diabetes patients in outpatient settings 
were consecutively enrolled as a hospital-based cohort and 
a cross-sectional case-controlled study was designed. Two 
hundred and seventeen of these patients (132 males) were 
designated as cases with diabetic complications and 60 (42 
males) were controls without apparent diabetic complica-
tions. Diagnosis of type 2 diabetes was performed according 
to Japan Diabetes Society criteria. Patients with heart failure 
(New York Heart Association Functional Classification . 
II) and on hemodialysis were excluded, since levels of NT-
proBNP are strongly influenced. Also, patients with acute 
illness, malignancy, or pregnancy were excluded.
The examination included full medical histories, physical 
examinations, and blood samples. All patients underwent 
ophthalmologic examinations and were graded as back-
ground or proliferative retinopathy. Albumin excretion rate 
(AER), measured on two serial 24-hour urine   collections, 
was categorized as normoalbuminuria (,30 µg/min), 
microalbuminuria (30–300 µg/min), and   macroalbuminuria 
(.300 µg/min). Estimated glomerular filtration rate (eGFR) 
was calculated by the equation from the Modification of Diet 
in Renal Disease study for Japanese using the four-compo-
nent abbreviated equation:
eGFR (mL/minute 1.73 m2) = 194× creatinin (Cr)–1.094 × 
age–0.287 (female ×0.739) (1)
Distal symmetrical polyneuropathy was diagnosed by the 
absence of ankle reflexes or abnormal vibration perception 
threshold by a 128 Hz tuning fork on the big toe and the loss 
of touch sensation by a 10 g Monotouch filament on the sole 
of the foot. CVD was defined as a composite of a history of 
myocardial infarction, angina, coronary artery bypass graft, 
or procedures of angioplasty, ischemic strokes, or transient 
ischemic attacks. Peripheral artery disease (PAD) was defined 
by a history of intermittent claudication, vascular interven-
tion, or amputation concomitant with a decreased ankle 
brachial index ,0.9.
In the present study, diabetic complications were defined 
as DMR, nephropathy, neuropathy, CVD, and PAD. Left 
ventricular hypertrophy (LVH) was defined by the electrocar-
diogram criteria (S V1+R V5 or V6 .35 mm). Brachioankle 
pulse wave velocity (baPWV) was measured by form ABI/
PWV (Omron Colin, Komaki, Japan). Serum NT-proBNP 
levels were measured by a two-site sandwich electrochemi-
luminescence immunoassay (ECLusys proBNP; Hoffman-La 
Roche Ltd, Basel, Switzerland).
The Institutional Review Board of Kanto Rosai Hospital 
approved the study protocol, and all the participants gave 
written informed consent. Variables distributed normally 
are presented as means (standard deviation), while variables 
with skewed distribution were analyzed after logarithmic 
transformation (NT-proBNP; AER). Variables were compared 
by a Student’s t-test or one-way analysis of variance. Pearson 
correlation analyses were performed to analyze the associa-
tions between NT-proBNP and other numerical variables. 
To assess the pattern of odds ratios (ORs) across increasing 
NT-proBNP values, the NT-proBNP values were categorized 
by the tertile distribution.
Logistic regression analysis was used separately to esti-
mate the ORs of NT-proBNP for any complication, and 95% 
confidence interval (CI) was given. Adjustment confounding 
variables were age, sex, duration of diabetes, body mass index 
(BMI), and hemoglobin A1c (HbA1c). A P-value of ,0.05 was 
considered to be statistically significant. All reported P-values 
are two-sided. All analysis was performed using JMP version 
9.0.0 (SAS Institute Inc., Cary, NC, USA).
Results
The characteristics of subjects are shown in Table 1. The 
NT-proBNP levels were negatively associated with eGFR 
and positively with age (data not shown) in accordance with 
previous reports. Levels of NT-proBNP were also corre-
lated with electrocardiogram LVH (r=0.212; P,0.001) and 
baPWV (r=0.449; P,0.0001).Vascular Health and Risk Management 2014:10 submit your manuscript | www.dovepress.com
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compared to that in the lowest tertile. Many of the subjects 
had more than one complication, and, as a consequence, the 
number of complications increased progressively through the 
tertiles of NT-proBNP. This tendency was observed even after 
adjustment for age, sex and duration of diabetes.
Discussion
In the present study, we showed that NT-proBNP elevation 
was associated with diabetic microvascular complications. 
We also demonstrated that NT-proBNP was correlated with 
surrogate markers of cardiac and vascular structural change, 
namely LVH or vascular stiffness (baPWV). It may be argued 
that increased NT-proBNP in patients with diabetes might 
be explained by minimally reduced glomerular filtration.   
It was shown that increased BNP has been found in patients 
with impaired renal function than healthy controls, and yet 
urinary NT-proBNP was positively correlated with increased 
plasma NT-proBNP.11,12
These inverse correlations between renal function and uri-
nary NT-proBNP indicate that renal retention is not the only 
reason for increased NT-proBNP, suggesting an increased 
release of BNP and NT-proBNP from cardiac myocytes. In 
fact, in a previous paper, we have shown a good correlation 
of NT-proBNP and cardiac parameters.4 Recently, subclini-
cal abnormalities in cardiac structure have been associated 
with longitudinal kidney function decline indicating a close 
relationship of two organs, ie, cardiorenal continuum.13
The novel point of the present results is that subjects 
with higher NT-proBNP had diabetic complications, such as 
DMR, DSN, and PAD, the target organs not directly related 
to kidney or heart. Similar results have just been shown 
in a large cohort of type 1 diabetes.7 It is conceivable that 
the longer the duration of diabetes, the worse the kidney 
function, and advanced age – all together – contribute to 
the elevation of NT-proBNP. However, in the present study, 
elevation of NT-proBNP was associated with DSN or DMR 
independent of disease duration in addition to kidney func-
tion or age. Data regarding the association between DSN and 
NT-proBNP levels were scarce and repetitive microhypoxic 
insults to nerve fibers’ arterial supply was suggested by 
Jurado et al in a group of type 2 diabetic patients.14
Moreover, subjects with strokes (data not shown) or PAD 
had higher NT-proBNP even with normal kidney and cardiac 
status. A similar finding has been recently reported in a 
Japanese large scale general population cohort study.15
A variety of factors other than myocardial stretch have 
been shown to stimulate secretion of BNP, such as myocardial 
ischemia, endocrine and paracrine factors such as endothelin, 
Table 1 Characteristics of subjects with and without diabetic 
complications
Case  
subjects*
Control  
subjects
P
Number 217 60
Age (years) 63.4±12.0 54.1±13.6 ,0.0001
Diabetes duration 
(years) 
9 (3–17) 4 (1–11) 0.0029
Males (%) 60.8% 70.0% 0.1933
BMI (kg/m2) 26.3±4.9 25.9±5.3 0.5466
HbA1c (%) 8.7±2.0 (71.6) 8.5±2.3 (69.4) 0.4404
SBP (mmHg) 136.4±19.6 130.3±16.8 0.0270
DBP (mmHg) 79.0±12.5 77.7±10.4 0.4525
Total cholesterol  
(mg/dL) 
195.1±37.9 199.0±49.8 0.5918
LDL  
cholesterol (mg/dL)
117.2±33.6 122.8±37.7 0.2733
HDL  
cholesterol (mg/dL)
55.1±16.1 56.9±17.3 0.4528
Triglycerides (mg/dL) 140 (104–214) 151 (107–231) 0.7500
NT-proBNP (pg/mL) 59 (26–140) 33 (16–58) ,0.0001
Smoking (%) 24.2% 24.4% 0.5040
Albuminuria (μg/min) 24.9 (9.0–92.8) 8.2 (5.4–15.7) ,0.0001
IMTR 1,788±431 1,504±301 ,0.0001
IMTL 1,813±568 1,522±303 0.0003
PWVR 1.12±0.14 1.14±0.08 0.4128
PWVL 1.11±0.14 1.14±0.09 0.0939
ABIR 2.61±0.87 2.49±0.65 0.3652
ABIL 71.6±23.5 79.8±20.4 0.0147
Notes: Data are mean ± SD. *Presence of any of diabetic complications (DMR, 
nephropathy, DSN, CVD, and PAD). P-values in bold were demonstrated to have 
adequate effect size.
Abbreviations: BMI, body mass index; HbA1c, hemoglobin A1c; SBP, systolic blood 
pressure; DBP, diastolic blood pressure; LDL, low-density lipoprotein; HDL, high-
density  lipoprotein;  NT-proBNP,  N-terminal  fragment  of  probrain  natriuretic 
peptide; IMTL, intima media thickness of left carotid; IMTR, intima media thickness 
of  right  carotid;  PWV,  pulse  wave  velocity;  ABI,  ankle  brachial  index;  LVH,  left 
ventricular hypertrophy; eGFR, estimated glomerular filtration rate; R, right; L, left; 
SD, standard deviation; CVD, cardiovascular disease; PAD, peripheral artery disease; 
DMR, diabetes mellitus retinopathy; DSN, distal sensory neuropathy.
The NT-proBNP values were significantly higher in cases 
with any of the complications (DMR, DSN [distal sensory 
neuropathy], nephropathy, CVD, and PAD) than controls (59 
versus 33 pg/mL; P,0.0001). The effect size for NT-proBNP 
was 0.26. Of the 217 cases, DMR was present in 74 (back-
ground, 83.7%; proliferative, 16.3%). Nephropathy was present 
in 97 (microalbuminuria, 78.4%; macroalbuminuria, 21.6%) 
and DSN in 97 cases. CVD was present in 88 (ischemic heart 
disease, 63.6%; strokes, 36.4%) and 28 cases had PAD.
In logistic regression analysis adjusted for age, sex, dura-
tion of diabetes, BMI, and HbA1c, those in the higher tertiles 
(.79 pg/mL) had significantly higher ORs for all complica-
tions as well as for each complication examined separately 
compared to subjects in the lower tertile (,31 pg/mL) (Table 2).   
It is noteworthy that OR for DMR is prominent as 13.78 
(95% CI 3.34–70.75) in the highest tertile of NT-proBNP, Vascular Health and Risk Management 2014:10 submit your manuscript | www.dovepress.com
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angiotensin II, and tumor necrosis factor α (TNFα). In the 
most recent report in type 1 diabetes, TNFα was postulated 
as a key molecule for the elevation of BNP and was shown 
to play an important role in the development of diabetic 
complications.10
Unfortunately, in the present study, the TNFα or other 
cytokines were not measured. Another possibility is that 
cardiac biomarkers may represent systemic vascular inflam-
mation or oxidative stress that may have impact on disease 
progression in systemic vasculature.
There are several limitations in the present study. First, the 
conclusions may be limited, due to the small number of the 
subjects. Second, the diagnostic criteria are based on clinical 
practice, and we might have underestimated the prevalence of 
complications, such as silent myocardial ischemia. Third, in 
the present study, nonclassical diabetic complications, such 
as periodontal disease, cognitive function, or depression, 
were not evaluated.
In the context of clinical practice under limited resources, 
aggressive and expensive imaging procedures are not neces-
sary for all diabetic patients; instead, a reliable and simple 
biomarker focusing on classical complications is helpful to 
identify individuals at high risk.
The major point of our findings is that NT-proBNP might 
be a universal biomarker for detecting diabetic vascular 
complications. It is suggested that the complex interplay 
of heart, kidney, and other vasculature may happen very 
early in diabetes.8 It is necessary to explore the causal 
Table 2 ORs for diabetes complications by serum NT-proBNP values
NT-proBNP level (pg/mL) P for trend Log-NT- 
proBNP (pg/mL)
P for trend
1st tertile 
(,31)
2nd tertile (31–78) 
OR (CI)
3rd tertile (79∼) 
OR (CI)
Total diabetes complications (N=217)
(a∼e)
1)  No adjustment 1.00 1.18 (0.62–2.27) 6.10 (2.52–17.14) ,0.0001 3.51 (2.03–6.43) ,0.0001
2)    Adjusted for age,  
sex, duration
1.00 0.84 (0.40–1.77) 4.14 (1.37–15.59) 0.0081 2.32 (1.21–4.74) 0.0101
3)  Full adjustment 1.00 0.96 (0.44–2.09) 5.04 (1.60–19.63) 0.0051 2.60 (1.32–5.53) 0.0084
a) CVD (n=88)
1)  No adjustment 1.00 2.51 (1.15–5.64) 15.09 (5.66–46.17) ,0.0001 11.15 (4.77–30.57) ,0.0001
2)    Adjusted for age,  
sex, duration
1.00 1.66 (0.67–4.14) 8.30 (2.48–33.57) 0.0014 5.66 (2.29–16.69) ,0.0001
3)  Full adjustment 1.00 1.85 (0.71–4.91) 9.33 (2.70–38.99) 0.0010 6.34 (2.44–20.21) ,0.0001
b) nephropathy (n=97)
1)  No adjustment 1.00 0.80 (0.37–1.73) 5.95 (2.31–17.56) ,0.0001 3.08 (1.75–5.82) ,0.0001
2)    Adjusted for age,  
sex, duration
1.00 0.64 (0.26–1.51) 4.90 (1.47–19.83) 0.0015 2.42 (1.23–5.21) 0.0100
3)  Full adjustment 1.00 0.73 (0.29–1.84) 6.23 (1.77–26.78) 0.0012 2.71 (1.33–6.11) 0.0052
c) DSN (n=135)
1)  No adjustment 1.00 1.48 (0.73–3.01) 6.94 (2.75–20.16) ,0.0001 5.55 (2.77–12.45) ,0.0001
2)    Adjusted for age,  
sex, duration
1.00 1.12 (0.50–2.48) 4.87 (1.54–18.84) 0.0124 3.75 (1.70–9.42) 0.0007
3)  Full adjustment 1.00 1.35 (0.58–3.19) 6.60 (1.97–27.16) 0.0048 5.17 (2.13–15.04) ,0.0001
d) DMR (n=74)
1)  No adjustment 1.00 2.08 (0.88–5.06) 11.77 (4.18–37.88) ,0.0001 10.49 (4.26–30.81) ,0.0001
2)    Adjusted for age,  
sex, duration
1.00 1.97 (0.72–5.53) 10.40 (2.72–48.47) 0.0017 8.79 (3.05–31.09) ,0.0001
3)  Full adjustment 1.00 2.75 (0.94–8.45) 13.78 (3.34–70.75) 0.0008 12.10 (3.62–54.23) ,0.0001
e) PAD (n=28)
1)  No adjustment 1.00 1.13 (0.19–6.59) 34.50 (8.78–184.83) ,0.0001 25.72 (7.07–140.34) ,0.0001
2)    Adjusted for age,  
sex, duration
1.00 1.32 (0.19–9.61) 40.86 (5.84–481.87) ,0.0001 13.11 (3.20–82.70) 0.0001
3)  Full adjustment 1.00 1.14 (0.10–11.75) 86.79 (9.23–1,632.73) ,0.0001 19.74 (4.03–171.38) ,0.0001
Notes: model 1, no adjustment; model 2, adjusted for age, sex, and log-duration of diabetes; model 3, full adjustment (model 2 plus BMI, HbA1c).
Abbreviations: OR, odds ratio, CI, confidence interval; NT-proBNP, N-terminal fragment of probrain natriuretic peptide; CVD, cardiovascular disease; DSN, distal sensory 
neuropathy; DMR, diabetes mellitus retinopathy; PAD, peripheral artery disease; BMI, body mass index; HbA1c, hemoglobin A1c.Vascular Health and Risk Management
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relationships between BNP and the systemic vasculatures 
in diabetes.
In conclusion, the stable and reproducible assay of NT-
proBNP might be widely used in clinical settings, and it is 
possible to stratify high risk subjects among diabetics and 
implement intensive interventions.
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